Federal Circuit Affirms Doctrine of Equivalents Analysis Using Appropriate Hypothetical Claim

Federal Circuit buildingIntendis GMBH v. Glenmark Pharmaceuticals Inc., USA, Glenmark Pharms., Inc. (Fed. Cir. May 16, 2016) (Before Taranto, Moore, and Prost, C J.) (Opinion for the court, Moore, J.) Click Here for a copy of the opinion.

Bayer Healthcare Pharmaceuticals holds a New Drug Application (NDA) for Finacea® Gel, which is “a topical medication for various skin disorders.” The FDA’s Orange Book lists the ‘070 patent as covering this gel. Glenmark submitted its Abbreviated New Drug Application (ANDA) to the FDA seeking to market a generic version of the gel as well as a paragraph IV certification asserting that the ‘070 patent was invalid and not infringed. The generic gel substituted isopropyl myristate for the claimed triglyceride and lecithin.

The district court held a Markman hearing and a bench trial on infringement and validity. Using the function-way-result test, the district court had determined that the ‘070 patent had been infringed under the doctrine of equivalents (DOE), and that the patent was not invalid. Specifically, the court concentrated on the fact that Glenmark’s generic product met the claim elements of the ingredients used by Bayer, under the doctrine of equivalents. The court rejected Glenmark’s claims that such infringement would encompass the prior art, and that it was barred by prosecution history estoppel. The district court also rejected Glenmark’s argument of obviousness. The court directed the FDA not to approve Glenmark’s ANDA until after the ‘070 patent expired.   Glenmark appealed.

[Troutman-Ad]

The Federal Circuit held that it is not the case that a patent must spell out a claim element’s function, way, and result, for the doctrine of equivalents to apply. It looked to what the claim element’s function in the claimed composition is to one of skill in the art, which it held may be determined by looking at extrinsic evidence. The Court found no error in the district court’s finding of infringement under the doctrine of equivalents. In applying the two part test (constructing a hypothetical claim that covers the accused device and comparing that claim to the prior art), the district court correctly determined that the hypothetical claim properly included the disputed excipients, i.e. Glenmark’s excipient. The district court properly rejected Glenmark’s argument that the hypothetical claim must encompass all penetration enhancers, i.e. prior art enhancers.

The Court also affirmed the district court’s analysis in determining that prosecution history estoppel did not bar a DOE finding. Glenmark argued that the ‘070 patent applicants surrendered a lecithin-free composition, which is the proposed generic product, as an equivalent during prosecution because two dependent claims which recited lecithin concentrations of up to 1% and 3% could include zero lecithin. Applicants argued that those ranges did not include zero because they are depend from claims which clearly required lecithin. The Court disagreed, because a dependent claim can never be broader than its independent claim.

The Court also affirmed the district court’s determination of non-obviousness, finding that a skilled artisan would not have been motivated to combine the prior art, and there was no reasonable expectation of success based on the evidence of record. For all the reasons above, the Court affirmed the district court.

Parker Hancock and Puja Dave contributed to this summary.

[Troutman-About]

The Author

Robert Schaffer

Robert Schaffer is an intellectual property partner at Troutman Sanders. Bob applies more than 30 years of experience to IP counseling and litigation. His work includes patent procurement, strategic planning and transactional advice, due diligence investigations, district court patent cases, and Federal Circuit appeals. He regularly handles complex and high-profile domestic and international patent portfolios, intellectual property agreements and licensing, IP evaluations for collaborations, mergers, and acquisitions. In disputed court cases Bob’s work includes representing and counseling client in ANDA litigations, complex patent infringement cases and appeals, and multidistrict and international cases. In disputed Patent Office matters his work includes representing and counseling clients in interferences, reexaminations, reissues, post-grant proceedings, and in European Oppositions. For more information and to contact Bob please visit his profile page at the Troutman Sanders website.

Robert Schaffer

Joseph Robinson has over 20 years of experience in all aspects of intellectual property law. He focuses his practice in the pharmaceutical, life sciences, biotechnology, and medical device fields. His practice encompasses litigation, including Hatch-Waxman litigation; licensing; counseling; due diligence; and patent and trademark prosecution. He has served as litigation counsel in a variety of patent and trademark disputes in many different jurisdictions, and has also served as appellate counsel before the Court of Appeals for the Federal Circuit. Joe also focuses on complex inter partes matters before the U.S Patent and Trademark Office, inventorship disputes, reexaminations and reissues. His experience includes numerous interferences, a particular advantage in new U.S. Patent and Trademark Office post-grant proceedings. He also counsels on patent–related U.S. Food and Drug Administration issues, including citizen petitions, Orange Book listing, and trademark issues. For more information and to contact Joe please visit his profile page at the Troutman Sanders website.

Warning & Disclaimer: The pages, articles and comments on IPWatchdog.com do not constitute legal advice, nor do they create any attorney-client relationship. The articles published express the personal opinion and views of the author and should not be attributed to the author’s employer, clients or the sponsors of IPWatchdog.com. Read more.

Discuss this

There are currently No Comments comments.